<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986569</url>
  </required_header>
  <id_info>
    <org_study_id>FES13001</org_study_id>
    <nct_id>NCT01986569</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase III, Open Label, Non-randomized, Single Center Study to Evaluate Diagnostic Accuracy and Safety of Fluorine-18 (18F) Fluoroestradiol PET/CT in the Assessment of ER Status of Recurrent or Metastatic Lesions in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard diagnostic workup for recurrent or metastatic breast cancer includes biopsy and&#xD;
      determination of tumor estrogen status according to National Comprehensive Cancer Network and&#xD;
      European Society for Medical Oncology. Immunohistochemistry (IHC) is currently the most&#xD;
      commonly used method for determining ER status. A investigational imaging tracer named&#xD;
      16-alpha-[18F]-fluoro-17-beta-estradiol, or [18F]fluoroestradiol ([18F]FES) acts similarly in&#xD;
      vivo to estradiol and binds to estrogen receptors (ERs). Previous studies in human have shown&#xD;
      the efficacy of [18F]FES PET in detecting ER positive breast cancer without any observed&#xD;
      toxicity. The investigators hypothesized that [18F]FES PET imaging can noninvasively assess&#xD;
      ER status in recurrent or metastatic breast cancer lesion . In this study, a positive and&#xD;
      negative percent agreement between IHC and [18F]FES will be determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lesion-level positive and negative percent agreement between qualitative [18F]FES PET interpretation and reference IHC testing</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>[18F]fluoroestradiol (FES)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]fluoroestradiol (FES)</intervention_name>
    <description>[18F]FES PET/CT will be performed 90 min (± 10 min) after administration of [18F]FES. Patients will undergo core needle biopsy or surgery within 15 days after [18F]FES PET; or patients will undergo core needle biopsy within 30 days before [18F]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.</description>
    <arm_group_label>[18F]fluoroestradiol (FES)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A patient will be enrolled if the patient meets the following inclusion criteria&#xD;
&#xD;
               1. Patient is ≥19 years of age and male or female of any race/ethnicity&#xD;
&#xD;
               2. Patients has first recurrence or stage IV disease by American Joint Committee on&#xD;
                  Cancer tumor-node-metastasis staging system for breast cancer&#xD;
&#xD;
               3. Patients had histologically confirmed invasive primary breast carcinoma and the&#xD;
                  documented results of histology are available.&#xD;
&#xD;
               4. Patients are scheduled to undergo core needle biopsy or surgery for histological&#xD;
                  confirmation and determination of ER status of recurrent or distant metastatic&#xD;
                  cancer within 15 days after [18F]FES PET; or patients already underwent core&#xD;
                  needle biopsy of recurrent or distant metastatic cancer within 30 days before&#xD;
                  [18F]FES PET and biopsy specimens are available for determination of ER status.&#xD;
&#xD;
               5. Discontinuation of selective ER blocking agents including tamoxifen or&#xD;
                  fulvestrant for at least 60 days prior to [18F]FES PET&#xD;
&#xD;
               6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient will be excluded from this study if the patient does not full fulfill the&#xD;
             inclusion criteria, or if any of the following conditions are observed&#xD;
&#xD;
               1. Patient or patient's legally acceptable representative do not provide written&#xD;
                  informed consent&#xD;
&#xD;
               2. The recurrent or metastatic lesion scheduled to undergo biopsy is located in&#xD;
                  breast, liver, ovary, uterus, or bone&#xD;
&#xD;
               3. Female patient is pregnant or nursing. Exclusion of the possibility of pregnancy&#xD;
                  is made by one of the following: 1) woman is physiologically post menopausal&#xD;
                  (cessation of menses for more than 2 years), 2) woman is surgically sterile (has&#xD;
                  had a documented bilateral oophorectomy and/or documented hysterectomy, or 3) if&#xD;
                  the woman is of childbearing potential, a urine pregnancy test performed within&#xD;
                  24 hours immediately prior to administration of [18F]FES has to be negative and&#xD;
                  the women is advised to apply contraceptive measures during her participation in&#xD;
                  this study&#xD;
&#xD;
               4. Adjuvant chemotherapy within 3 weeks prior to [18F]FES PET.&#xD;
&#xD;
               5. Radiation therapy or immuno/biologic therapy is scheduled to be given to patient&#xD;
                  before the histologic confirmation by biopsy or [18F]FES PET.&#xD;
&#xD;
               6. Concurrent severe and/or uncontrolled and/or unstable medical disease other than&#xD;
                  cancer (e.g. congestive heart failure, acute myocardial infarction, severe&#xD;
                  pulmonary disease, chronic renal or hepatic disease which could compromise&#xD;
                  participation in the study) in the judgment of the investigator.&#xD;
&#xD;
               7. Patient is a relative of the investigator, student of the investigator or&#xD;
                  otherwise dependent&#xD;
&#xD;
               8. Patient has any other condition or personal circumstances that, in the judgment&#xD;
                  of the investigator, might interfere with the collection of complete data&#xD;
&#xD;
               9. Patient has been involved in an investigative, radioactive research procedure&#xD;
                  within 7 days prior to registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Hyuk Moon, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/breast-cancer</url>
    <description>Genetics Home Reference related topics; breast cancer</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/breastcancer.html</url>
    <description>MedlinePlus related topics; Breast cancer</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Dae Hyuk Moon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Fluoroestradiol (FES)</keyword>
  <keyword>PET/CT scan</keyword>
  <keyword>Estrogen Receptor</keyword>
  <keyword>Recurrent breast cancer</keyword>
  <keyword>Stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

